Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...

These Catalent sites are already involved in Novo Nordisk manufacturing contracts, which are largely tied to ramping up supply of the firm’s obesity drug Wegovy. Novo Nordisk expects that ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Shares of weight-loss drugmakers like Novo Nordisk and Eli Lilly surged after President Biden proposed expanding anti-obesity drug coverage under state health plans. The move could reduce ...

Novo Nordisk is ceasing production of human insulin pens, focusing on newer obesity and diabetes injections. This shift has ...

Against a backdrop of manufacturing prioritisation, Novo Nordisk’s contract with Swiss medical technology Ypsomed could include the supply of injection pens for CagriSema, the former’s ...

On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...

Pharmaceutical contract manufacturing is when a company hires a third-party to produce drugs for them. The report by ...